Skip to main content

Table 2 Adverse events of CPT-11/NDP chemotherapy

From: UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

UGT1A1

Wild-type (24 cases)

Polymorphism (hetero/homo, n = 23/4 cases)

P-value

Neutropenia

7

15

0.09

Grade 3

5

12

0.13

Grade 4

2

3

> 0.99

Febrile neutropenia

1

1

>  0.99

Nausea (> Grade 3)

1

2

>  0.99

Diarrhea (> Grade 3)

4

3

0.69

Anorexia (> Grade 3)

0

2

0.49

Thrombocytopenia (> Grade 3)

0

1

>  0.99

  1. CPT-11/NDP Irinotecan/nedaplatin, UGT1A1 Uridine diphosphate glucuronosyltransferase 1 family polypeptide A1